



02-23-05

B1/1621

CASE 4-30096B

EPW

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV336718644US

Express Mail Label Number

February 22, 2005

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1621

ZIMMERMANN ET AL.

Examiner: O'Sullivan, Peter G.

APPLICATION NO: 09/991,184

FILED: NOVEMBER 16, 2001

FOR: CRYSTAL MODIFICATION OF A N-PHENYL-2-PYRIMIDINEAMINE
DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND ITS
USE

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Petition to Correct Inventorship


Sir:

It has come to the Applicants' attention, that the inventorship for the above-identified application is incorrect. The reason for the change of inventorship is due to the amendments to the claims which define subject matter originally described but not claimed in the original specification.

This petition is accompanied by a "substitute" declaration and power of attorney executed by the actual inventor of the pending claims.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852


Oona A. Jackson
Attorney for Applicant
Reg. No. 48,152

Date: 2/22/05



Case 4-30096B

"SUBSTITUTE"

DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATIONS

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled

CRYSTAL MODIFICATION OF A N-PHENYL-2-PYRIMIDINEAMINE DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND ITS USE

the specification of which was filed on November 16, 2001 as U.S. Application No. **09/991,184.**

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims.

I acknowledge my duty to disclose all information which is known by me to be material to the patentability of this application as defined in 37 C.F.R. §1.56.

I hereby claim the benefit under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate listed below and under 35 U.S.C. §365(a) of any PCT international application(s) designating at least one country other than the United States listed below and have also listed below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application the priority of which is claimed for that subject matter:

<u>Country, Region or PCT</u>	<u>Application No.</u>	<u>Filing Date</u>	<u>Priority Claimed</u>
Switzerland	1764/97	July 18, 1997	Yes

I hereby claim the benefit under 35 USC §119(e) of any United States provisional application(s) listed below:

None



I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) listed below and under 35 U.S.C. §365(c) of any PCT international application(s) designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose all information known by me to be material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date(s) of the prior application(s) and the national or PCT international filing date of this application:

<u>United States Application No.</u>	<u>United States Filing or §371 Date</u>	<u>Status or U.S. Patent No.</u>	<u>International Application No.</u>	<u>International Filing Date</u>
09/463,097	January 18, 2000	Pending	PCT/EP98/04427	July 16, 1998

I hereby appoint the attorneys and agents associated with Customer No. 001095, respectively and individually, as my attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.


Please address all communications to the address associated with Customer No. 001095, which is currently , Novartis, Corporate Intellectual Property, One Health Plaza, Building 104, East Hanover, NJ 07936-1080.


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



SOLE INVENTOR:

Full name : **Pekka Hayry**

Signature : 

Date : 
(MM/DD/YY)

Citizenship : Finland

Residence : Helsinki, Finland

P.O. Address : Valskarinkatu 3 A 12
FIN 00260 Helsinki
Finland

IMPORTANT: Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.